Altre lingue Plus Therapeutics, Inc.

Azioni

PSTV

US72941H5090

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 05/07/2024			Variaz. 5gg	Var. 1 gen.
1,55 ^USD	+1,31%		+5,44%	-11,43%

07/06	Plus Therapeutics, Inc. riceve le dimissioni del Dr. Norman Lafrance, suo Direttore Medico, con effetto dal 12 giugno 2024	CI
07/06	Plus Therapeutics riceverà un anticipo di 3,3 milioni di dollari dal CPRIT per il programma di sviluppo radioterapico	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer	02/07
Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases Phase 1 Dose Escalation Trial: Update for Initial Safety, Feasibility and Preliminary Efficacy	11/06
Plus Therapeutics, Inc. Receives the Resignation of Dr. Norman Lafrance, Its Chief Medical Officer, Effective June 12, 2024	07/06
Plus Therapeutics to Receive $3.3 Million Advance Payment From CPRIT For Radiotherapeutic Development Program	07/06
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT	07/06
Plus Therapeutics, Inc. Draws $3.3 Million on Its Existing Margin Loan Facility with Pershing Llc	04/06
Plus Therapeutics Announces New Employment Inducement Grants	17/05
Plus: Q1 Earnings Snapshot	15/05
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	15/05
Plus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024	13/05
Plus Therapeutics : Material Agreement - Form 8-K	10/05
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial	09/05
Plus Therapeutics, Inc. acquired CNSide, a leptomeningeal metastases diagnostic platform.	09/05
Plus Therapeutics, Inc. announced that it has received $7.262078 million in funding from Aigh Capital Management, LLC	09/05
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial	08/05
Plus Therapeutics : The use of CNSide in Clinical Management of LMD	08/05
Plus Therapeutics Announces Private Placement Financing of up to $18 Million	06/05
Plus Therapeutics, Inc. announced that it expects to receive $6.548504 million in funding from Aigh Capital Management, LLC	05/05
Plus Therapeutics : Nuclear Medicine and Neurooncology (NMN) Symposium 2024	29/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Plus Therapeutics, Inc.

Azioni

PSTV

US72941H5090

Altre lingue

Filtri